Skip to main content

Quest Diagnostics Inc (DGX)

Health Services Health Care
Stock AI

Financial Metrics

Price to Earnings24.71x
Revenue Growth (1Y)9.87%
Debt to Equity0.77x

Strengths

Stock Chart

Valuation

Quest Diagnostics Inc is overvalued

News

All
Press Releases
News
Filings
 Quest Diagnostics Declares Quarterly Cash Dividend
August 12, 2026 Quest Diagnostics Declares Quarterly Cash Dividend
 Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
July 30, 2026 Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
 Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
July 23, 2026 Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
10-Q Quarterly Report for 2026 Q2
July 23, 202610-Q Quarterly Report for 2026 Q2
More U.S. Workers Are Testing Positive for Marijuana. Fewer Employers Are Concerned.
July 10, 2026More U.S. Workers Are Testing Positive for Marijuana. Fewer Employers Are Concerned.
 One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns
July 10, 2026 One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns
 Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
July 08, 2026 Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
 Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
June 24, 2026 Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
 UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
June 18, 2026 UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
 Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
June 17, 2026 Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
 Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
June 16, 2026 Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
 Quest Diagnostics Declares Quarterly Cash Dividend
May 19, 2026 Quest Diagnostics Declares Quarterly Cash Dividend
 Quest Diagnostics Prices $500 Million of Senior Notes
April 27, 2026 Quest Diagnostics Prices $500 Million of Senior Notes
10-Q Quarterly Report for 2026 Q1
April 22, 202610-Q Quarterly Report for 2026 Q1
Quest Diagnostics Gains Steam With Partnerships, Lifts Outlook
April 21, 2026Quest Diagnostics Gains Steam With Partnerships, Lifts Outlook
 Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
April 21, 2026 Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
 City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers
April 16, 2026 City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers
 Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026
March 19, 2026 Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026
 Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors
March 12, 2026 Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors
 Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results
March 02, 2026 Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results
 Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
February 26, 2026 Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
10-K Annual Report for 2025 FY
February 26, 202610-K Annual Report for 2025 FY
 Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference
February 25, 2026 Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference
Quest Diagnostics Stock Smashes 52-Week High On Strong Quarter, Dividend Hike
February 10, 2026Quest Diagnostics Stock Smashes 52-Week High On Strong Quarter, Dividend Hike
 Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
February 10, 2026 Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
 Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization
February 10, 2026 Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization
 Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
February 02, 2026 Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
 Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year
January 21, 2026 Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year
 Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium
January 06, 2026 Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium
 Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan
January 05, 2026 Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan
 Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
December 19, 2025 Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing
November 14, 2025Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing
 Quest Diagnostics Declares Quarterly Cash Dividend
November 11, 2025 Quest Diagnostics Declares Quarterly Cash Dividend
 Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference
November 03, 2025 Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference
 New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
October 27, 2025 New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
Price Over Earnings Overview: Quest Diagnostics
October 24, 2025Price Over Earnings Overview: Quest Diagnostics
Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings
October 22, 2025Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings
Quest Diagnostics Reports Q3 Earnings, Shares Slide
October 21, 2025Quest Diagnostics Reports Q3 Earnings, Shares Slide
Gold Sinks 5% On Worst Day In 5 Years, Dow Jones Hits Record Highs: What's Moving Markets Tuesday?
October 21, 2025Gold Sinks 5% On Worst Day In 5 Years, Dow Jones Hits Record Highs: What's Moving Markets Tuesday?
 Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
October 21, 2025 Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
10-Q Quarterly Report for 2025 Q3
October 21, 202510-Q Quarterly Report for 2025 Q3
 MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®
October 17, 2025 MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®
This Quest Diagnostics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
August 25, 2025This Quest Diagnostics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
10-Q Quarterly Report for 2025 Q2
July 23, 202510-Q Quarterly Report for 2025 Q2
Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks
July 22, 2025Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks
Lockheed, General Motors Tumble, Gold Hits 1-Month Highs: What's Moving Markets Tuesday?
July 22, 2025Lockheed, General Motors Tumble, Gold Hits 1-Month Highs: What's Moving Markets Tuesday?
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
July 21, 2025$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out
June 25, 2025Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
June 16, 2025Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
May 16, 2025$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
April 24, 2025Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
10-Q Quarterly Report for 2025 Q1
April 23, 202510-Q Quarterly Report for 2025 Q1
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
April 22, 2025Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Price Over Earnings Overview: Quest Diagnostics
April 15, 2025Price Over Earnings Overview: Quest Diagnostics
10-K Annual Report for 2024 FY
February 20, 202510-K Annual Report for 2024 FY
Quest Diagnostics Delivers Q4 Earnings Beat: The Details
January 30, 2025Quest Diagnostics Delivers Q4 Earnings Beat: The Details
10-Q Quarterly Report for 2024 Q3
October 23, 202410-Q Quarterly Report for 2024 Q3
10-Q Quarterly Report for 2024 Q2
July 24, 202410-Q Quarterly Report for 2024 Q2
More Are Cheating on Drug Tests
May 15, 2024More Are Cheating on Drug Tests
10-Q Quarterly Report for 2024 Q1
April 24, 202410-Q Quarterly Report for 2024 Q1
10-K Annual Report for 2023 FY
February 22, 202410-K Annual Report for 2023 FY
10-Q Quarterly Report for 2023 Q3
October 25, 202310-Q Quarterly Report for 2023 Q3
10-Q Quarterly Report for 2023 Q2
July 27, 202310-Q Quarterly Report for 2023 Q2
10-Q Quarterly Report for 2023 Q1
April 28, 202310-Q Quarterly Report for 2023 Q1
10-K Annual Report for 2022 FY
February 21, 202310-K Annual Report for 2022 FY
10-Q Quarterly Report for 2022 Q3
October 21, 202210-Q Quarterly Report for 2022 Q3
10-Q Quarterly Report for 2022 Q2
July 22, 202210-Q Quarterly Report for 2022 Q2
10-Q Quarterly Report for 2022 Q1
April 22, 202210-Q Quarterly Report for 2022 Q1
10-K Annual Report for 2021 FY
February 28, 202210-K Annual Report for 2021 FY
10-Q Quarterly Report for 2021 Q3
October 22, 202110-Q Quarterly Report for 2021 Q3

A. Company Overview

Quest Diagnostics Inc., established as a public company in 1990, has its origins rooted in various predecessor organizations dating back to 1967. Headquartered in Secaucus, New Jersey, the company operates through an extensive network of laboratories, patient service centers, and various facilities predominantly within the United States and selectively in international markets. Quest Diagnostics is recognized as one of the leading providers of diagnostic information services in the healthcare ecosystem, contributing to improved patient outcomes through an unwavering focus on quality service. In 2023, it reported net revenues of approximately $9.3 billion.

The company occupies a significant role within the healthcare landscape, serving the needs of a broad array of customers, including healthcare providers, patients, government agencies, and insurance organizations. Annually, Quest Diagnostics serves one-third of the adult population in the United States, with approximately half of the nation's physicians and hospitals relying on its extensive diagnostic testing services.

B. The Quest Way

The operational framework of Quest Diagnostics is governed by a set of principles termed “The Quest Way,” which encapsulates the organization’s mission to foster a healthier world, one life at a time. This framework comprises three pivotal components:

  1. Purpose: To collaboratively create a healthier world through laboratory diagnostics.
  2. Strategy: Focused on delivering innovative, high-quality, convenient, and affordable solutions that adapt to the evolving needs of customers.
  3. Culture: Built around the “5Cs” — customer-first, collaboration, care, continuous improvement, and curiosity, which together shape the internal ethos of the company.

This framework aligns with the foundational goals of enhancing medical quality and patient experience while simultaneously reducing the overall costs of healthcare. The company's emphasis on fostering an innovative and supportive work environment is believed to be instrumental in enabling employees to contribute effectively towards the overarching objective of improved health outcomes.

C. Business Strategy

Quest Diagnostics pursues a dual strategy directed at generating growth and optimizing operational efficiencies. Key elements of this strategy include:

  • Collaboration: Partnering with healthcare providers to leverage extensive reach and data insights.
  • Comprehensive Service Offerings: Delivering an extensive array of diagnostic tests across various specialties, included routine and advanced diagnostics.
  • Data Utilization: Utilizing its vast database of clinical lab results to enhance population health management and facilitate value-based care solutions.
  • Technological Innovation: Embracing automation and artificial intelligence to drive quality improvements and operational efficiencies across the organization.

This growth strategy is articulated through primary customer channels, including physicians, hospitals, and patients. It is supported by a consistent focus on quality improvement initiatives, which are bolstered by the application of the Quest Management System — a framework for maintaining high standards of performance across organizations.

D. Customer Segments

Physicians

Approximately half of the physicians in the United States utilize Quest Diagnostics' services, which include a broad spectrum of testing options tailored to various specialties. The company’s offerings are designed to provide a comprehensive suite of laboratory tests, enhancing accessibility, quality, and efficiency for healthcare providers.

Hospitals

Quest Diagnostics engages in partnerships with hospitals to offer reference testing services not performed in-house, support lab operations through Professional Laboratory Services, and acquire outreach lab operations. Such collaborations are seen as pivotal given the evolving challenges hospitals encounter in the healthcare landscape, including cost pressures, technology changes, and reimbursement models.

Patients and Consumers

In response to increasing consumer expectations for accessible healthcare services, Quest Diagnostics has reinforced its positioning as a consumer-friendly provider. The company operates over 2,000 patient service centers strategically located in convenient retail settings. Various initiatives, including the "Schedule at Check In" feature and mobile phlebotomy services, have been established to streamline patient experiences.

E. Advanced Diagnostics

The company’s offerings in Advanced Diagnostics™ encompass a variety of specialized services, particularly in molecular diagnostics and oncology. This segment includes traditional oncology testing and next-generation sequencing, enhancing the diagnostic capabilities in complex medical scenarios. Recent expansions in this area, including the acquisition of Haystack Oncology, have positioned Quest Diagnostics to benefit from the increasing demand for non-invasive testing solutions that enable better disease monitoring and treatment efficacy.

F. Acquisitions and Growth

Quest Diagnostics actively pursues strategic acquisitions that align with its business objectives and growth strategy. Notable recent acquisitions include laboratory service assets from prominent health systems, enhancing service offerings and extending market reach. The company has consistently aimed for disciplined investment criteria focused on long-term value creation, integrating new capabilities into its existing operational framework.

G. Quality and Operational Excellence

A cornerstone of Quest Diagnostics' mission is its commitment to quality and operational efficacy, which is pursued through comprehensive quality programs and the Quest Management System. The organization emphasizes continuous quality improvement and utilizes various data analytics tools to monitor and enhance laboratory operations rigorously. This systematic approach to quality management aims to address both regulatory compliance and the overall effectiveness of services provided.

H. Information Technology and Innovation

Quest Diagnostics leverages advanced IT infrastructure to enhance service delivery. The MyQuest® patient healthcare portal and robust electronic health record (EHR) connectivity exemplify the company's efforts in integrating technology to streamline patient engagement and improve provider workflows. Additionally, the engagement in research and development enables ongoing enhancements in test development and service delivery innovation.

Stock Infos

SectorHealth Care
IndustryHealth Services
CEOJames E. Davis

Dividends

Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.